Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)
CompletedOBSERVATIONAL
Enrollment
16
Participants
Timeline
Start Date
September 30, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2017
Conditions
Multiple Sclerosis
Trial Locations (1)
4031
Dep. Neurology, Hospital of the University of Basel, Basel
All Listed Sponsors
lead
University Hospital, Basel, Switzerland
OTHER
NCT01765361 - Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG) | Biotech Hunter | Biotech Hunter